Nadja Louw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadja Louw has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Krause
Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa
3 shared publications - Nadia Carstens
South African Medical Research Council (SAMRC) Genomics Platform, Cape Town, South Africa
3 shared publications Aimé Lumaka
Center for Human Genetics, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
2 shared publicationsKoen Devriendt
Center for Human Genetics, University Hospitals, University of Leuven, Leuven, Belgium
2 shared publicationsLaura M. Yates
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa
2 shared publications- Matthew E. Hurles
Wellcome Sanger Institute, Hinxton, UK
2 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-10
Copy number variant analysis by exome sequencing is an effective approach to optimize diagnostic yield for developmental disorders—the DDD-Africa study
Copy number variants (CNV) contribute significantly to the pathogenic variation associated with developmental disorders. CNV detection is often not included in standard exome sequencing (ES) analysis. Complementary methods such as chromosomal microarray are typically offered in diagnostic laboratories to diagnose pathogenic CNV. In this study, we aimed to develop an effective approach for incorporating CNV detection within our ES analysis process for the Deciphering Developmental Disorders in Africa (DDD-Africa) cohort. We analyzed ES data from 505 probands with a developmental disorder, applying a CNV detection approach that assessed data generated using the tools CANOES and XHMM. When available, parental ES data was used to assess inheritance patterns. We confirmed a diagnosis in 41/505 (8,1%) patients with 43 pathogenic CNV identified in the probands. There were 31 deletions and 12 duplications. Among the 26 probands with parental data, all identified CNV were de novo. The addition of CNV analysis to our ES analysis pipeline resulted in an 8.1% increase in diagnostic yield in the DDD-Africa cohort without additional laboratory cost. This offers a feasible approach which is likely to reduce analytical cost and is suitable for low- and middle-income countries where funding and resources for genomic medicine initiatives are limited.
- 9 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-10
Open AccessCopy number variant analysis by exome sequencing is an effective approach to optimize diagnostic yield for developmental disorders—the DDD-Africa study
Copy number variants (CNV) contribute significantly to the pathogenic variation associated with developmental disorders. CNV detection is often not included in standard exome sequencing (ES) analysis. Complementary methods such as chromosomal microarray are typically offered in diagnostic laboratories to diagnose pathogenic CNV. In this study, we aimed to develop an effective approach for incorporating CNV detection within our ES analysis process for the Deciphering Developmental Disorders in Africa (DDD-Africa) cohort. We analyzed ES data from 505 probands with a developmental disorder, applying a CNV detection approach that assessed data generated using the tools CANOES and XHMM. When available, parental ES data was used to assess inheritance patterns. We confirmed a diagnosis in 41/505 (8,1%) patients with 43 pathogenic CNV identified in the probands. There were 31 deletions and 12 duplications. Among the 26 probands with parental data, all identified CNV were de novo. The addition of CNV analysis to our ES analysis pipeline resulted in an 8.1% increase in diagnostic yield in the DDD-Africa cohort without additional laboratory cost. This offers a feasible approach which is likely to reduce analytical cost and is suitable for low- and middle-income countries where funding and resources for genomic medicine initiatives are limited.
- Open Access
- 27 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5) , e70224
Confirmation of Exome Sequencing Results Using Sanger Sequencing—Considerations in a Low‐Resource Setting
Background: Exome sequencing (ES) is now widely accepted as an appropriate first‐tier diagnostic test for developmental disorders (DD). International guidelines recommend that in diagnostic settings, ES findings be validated with an orthogonal method, such as Sanger sequencing, before reporting. However, more recent guidance recognizes that confirmatory testing for variants meeting strict quality criteria is redundant. Weighing up the cost to benefit ratio of this practice is crucial in settings where ES is not routinely implemented. The Deciphering Developmental Disorders in Africa (DDD‐Africa) study aims to enable equitable implementation of genomic medicine in low‐resourced settings, focusing on using ES in resolving DD in Africa. Methods: We performed confirmatory Sanger sequencing for the first 64 probands (70 variants) that underwent ES in which a variant of interest was identified. Strict quality parameters were key to diminishing the observation of false‐positive variants. Results: All high confidence variants identified by ES ( n = 38) were confirmed using Sanger sequencing and low confidence variants ( n = 32) were confirmed as false‐positive. Conclusion: Confirming ES results with an orthogonal approach like Sanger sequencing is unnecessary in a resource‐limited setting when robust, context‐informed quality thresholds are applied. This recommendation removes significant barriers to the implementation of genomic medicine and allows for accelerated genomic access globally.
- 27 April 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (5) , e70224
Open AccessConfirmation of Exome Sequencing Results Using Sanger Sequencing—Considerations in a Low‐Resource Setting
Background: Exome sequencing (ES) is now widely accepted as an appropriate first‐tier diagnostic test for developmental disorders (DD). International guidelines recommend that in diagnostic settings, ES findings be validated with an orthogonal method, such as Sanger sequencing, before reporting. However, more recent guidance recognizes that confirmatory testing for variants meeting strict quality criteria is redundant. Weighing up the cost to benefit ratio of this practice is crucial in settings where ES is not routinely implemented. The Deciphering Developmental Disorders in Africa (DDD‐Africa) study aims to enable equitable implementation of genomic medicine in low‐resourced settings, focusing on using ES in resolving DD in Africa. Methods: We performed confirmatory Sanger sequencing for the first 64 probands (70 variants) that underwent ES in which a variant of interest was identified. Strict quality parameters were key to diminishing the observation of false‐positive variants. Results: All high confidence variants identified by ES ( n = 38) were confirmed using Sanger sequencing and low confidence variants ( n = 32) were confirmed as false‐positive. Conclusion: Confirming ES results with an orthogonal approach like Sanger sequencing is unnecessary in a resource‐limited setting when robust, context‐informed quality thresholds are applied. This recommendation removes significant barriers to the implementation of genomic medicine and allows for accelerated genomic access globally.
- Open Access
Copy Number Variant analysis by exome sequencing is an effective approach to optimize diagnostic yield for developmental disorders – the DDD-Africa study
Copy number variants (CNV) contribute significantly to the pathogenic variation associated with developmental disorders. CNV detection is often not included in standard exome sequencing (ES) analysis. Complementary methods such as chromosomal microarray are typically offered in diagnostic laboratories to diagnose pathogenic CNV. In this study, we aimed to develop an optimal approach for incorporating CNV detection within our ES analysis process for the Deciphering Developmental Disorders in Africa (DDD-Africa) cohort. We analyzed ES data from 505 probands with a developmental disorder, applying a CNV detection approach that assessed data generated using the tools CANOES and XHMM. When available, parental ES data was used to assess inheritance patterns. We confirmed a diagnosis in 42/505 (8,3%) patients with 44 pathogenic CNV identified in the probands. There were 31 deletions and 13 duplications. Among the 27 probands with parental data, all identified CNV were de novo . The addition of CNV analysis to our ES analysis pipeline resulted in an 8.3% increase in diagnostic yield in the DDD-Africa cohort without additional laboratory cost. This approach offers a feasible approach which is likely to reduce analytical cost and is suitable for low- and middle-income countries where funding and resources for genomic medicine initiatives are limited.
Open AccessCopy Number Variant analysis by exome sequencing is an effective approach to optimize diagnostic yield for developmental disorders – the DDD-Africa study
Copy number variants (CNV) contribute significantly to the pathogenic variation associated with developmental disorders. CNV detection is often not included in standard exome sequencing (ES) analysis. Complementary methods such as chromosomal microarray are typically offered in diagnostic laboratories to diagnose pathogenic CNV. In this study, we aimed to develop an optimal approach for incorporating CNV detection within our ES analysis process for the Deciphering Developmental Disorders in Africa (DDD-Africa) cohort. We analyzed ES data from 505 probands with a developmental disorder, applying a CNV detection approach that assessed data generated using the tools CANOES and XHMM. When available, parental ES data was used to assess inheritance patterns. We confirmed a diagnosis in 42/505 (8,3%) patients with 44 pathogenic CNV identified in the probands. There were 31 deletions and 13 duplications. Among the 27 probands with parental data, all identified CNV were de novo . The addition of CNV analysis to our ES analysis pipeline resulted in an 8.3% increase in diagnostic yield in the DDD-Africa cohort without additional laboratory cost. This approach offers a feasible approach which is likely to reduce analytical cost and is suitable for low- and middle-income countries where funding and resources for genomic medicine initiatives are limited.